Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
James S ScottAndrew BaileyDavid ButtarRodrigo J CarbajoJon CurwenPaul R J DaveyRobert D M DaviesSébastien L DegorceCraig DonaldEric GanglRyan GreenwoodSam D GroombridgeTony JohnsonScott LamontMandy LawsonAndrew ListerChristopher J MorrowThomas A MossJennifer H PinkRadoslaw PolanskiPublished in: Journal of medicinal chemistry (2019)
Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.
Keyphrases
- estrogen receptor
- high resolution
- endothelial cells
- magnetic resonance
- molecular dynamics
- high throughput
- molecular dynamics simulations
- bone mineral density
- cross sectional
- ionic liquid
- single molecule
- magnetic resonance imaging
- liver injury
- induced pluripotent stem cells
- computed tomography
- single cell
- mass spectrometry
- childhood cancer